ALTERATION OF BONE MINERAL DENSITY IN BREAST CANCER FEMALE SURVIVORS ON CHEMOTHERAPY TREATMENT
AN INTEGRATIVE REVIEW
Keywords:
Breast neoplasms, Bone mineral density, ChemotherapyAbstract
Introduction: Chemotherapy for treatment of patients with breast cancer has increased the survival of this population. However, it can significantly reduce bone mineral density (BMD). Objective: To verify bone mineral density modifications in women with breast cancer undergoing chemotherapy, as well as their clinical characteristics and risk factors. Methods: Integrative review of papers published from 2006 to 2016, carried out through specific terms in PubMed and SciELO databases. Results: In that period, 898 papers were identified (897 in PubMed and 1 in SciELO). Among the six papers recovered, there was a considerable reduction in lumbar spine and femoral bone mass. For women submitted to chemotherapy, the main regimens associated with the reduction were doxorubicin and cyclophosphamide (AC), cyclophosphamide, methotrexate and 5-fluorouracil (CMF) and cyclophosphamide, epirubicin and 5-fluorouracil (FEC). In addition, there was greater BMD reduction among women aged more than 50 years, Caucasian and who presented early ovarian failure induced by chemotherapy. Conclusion: The use of chemotherapy for breast cancer may lead to bone mass loss, especially when AC, CMF and FEC are used in women aged more than 50 years and among those with early menopause due to this treatment.
Downloads
References
Silva BB, Fernandes RC, Martins KA, Machado MG. Influência da quimioterapia no peso corporal de mulheres com câncer de mama. Ciênc Saúde. 2010 Dec;21(3):245-52.
Georges SO, Braga CC, Martins KA. Variação ponderal e quimioterapia em mulheres com câncer de mama atendidas em serviço público. Mundo Saúde. 2014;38(3):260-8.
Chang CH, Chen SJ, Liu CY. Fracture Risk and Adjuvant Therapies in Young Breast Cancer Patients: A Population-Based Study. PLoS ONE. 2015;10(6):e0130725.
Pan K, Chlebowski RT, Simon MS, Ray RM, Livaudais-Toman J, Sullivan SD, et al. Medication use trajectories of portmenopausal breast cancer survivors and matched cancerfree controls. Breast Cancer Res Treat. 2016 Apr;156(3)567-76.
Harvey NC, Biver E, Kaufman JM, Bauer J, Branco J, Brandi ML, et al. The role of calcium supplementation in healthy musculoskeletal ageing: An expert consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Foundation for Osteoporosis (IOF). Osteoporos Int. 2016.
Feng X, McDonald JM. Disorders of bone remodeling. Annu Rev Pathol. 2011 Feb;6:121-45.
Klein-Nulend J, Bacabac RG. Bone adaptation and regeneration – New developments. Int J Mod Phys Conf Ser. 2012;17:34-43.
Zhu K, Hunter M, James A, Lim EM, Walsh JP. Associations between body mass index, lean and fat body mass and bone mineral density in middle-aged Australians: The Busselton Healthy Ageing Study. Bone. 2015;74:146-52.
Conde DM, Costa-Paiva L, Martinez EZ, Pinto-Neto AM. Bone mineral density in postmenopausal women with and without breast cancer. Rev Assoc Med Bras. 2012;58(6):673-8.
Islam M. Postmenopausal osteoporosis in obese women. J Biom Pharmacol Res. 2014;3(6).
Hadji P, Ziller M, Maskow C, Albert U, Kalder M. The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turn over in pre-menopausal women with breast cancer. Eur J Cancer. 2009;45(18):3205-12.
Turan Y, Kocaaga Z, Karakoyun-Celik O, Gurgan A, Duransoy A. Osteoporosis in women with breast cancer and its effect on quality of life: a pilot study. J BUON. 2009;14(2):239-43.
Loo WTY, Jin LJ, Cheung MNB, Chow LWC, Wang M. Combination of radiological and biochemical methods to assess bone mineral density of mandible in fullyedentulous patients after chemotherapy: a 5-year prospective study. Expert Opin Investig Drugs. 2010;19(Suppl. I):S109-15.
Cameron DA, Douglas S, Brown JE, Anderson RA. Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency? Breast Cancer Res Treat. 2010;123(3):805-14.
Oostra DR, Lusterberg MB, Reinbolt RE, Pan X, Wesolowski R, Shaoiro CL. Association of osteoprotegerin and bone loss after adjuvant chemotherapy in early-stage breast cancer. Mol Cell Endocrinol. 2015;402:51-6.
Tabatabai LS, Bloom J, Stewart S, Sellmeyer DE. FSH Levels Predict Bone Loss in Premenopausal Women Treated for Breast Cancer More Than One Year Treatment. J Clin Endocrinol Metab. 2016;101(3):1257-62.
Maclaran K, Panay N. Current concepts in premature ovarian insufficiency. Womens Health (LondEngl). 2015;11(2):169-82.
Khosla S, Melton LJ, Riggs BL. The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res. 2011;26(3):441-51.
Wu X, Cai H, Kallianpur A, Li H, Yang G, Gao J, et al. Impact of Premature Ovarian Failure on Mortality and Morbidity among Chinese Women. PLoS ONE. 2014;9(3):e89597.
Sheri A, Dowsett M. Predicting response to cytotoxic drugs-the endocrine part of the story. Breast. 2011 Oct;20(Suppl. 3):S28-30.
Fabian CJ, Kimler BF, Zalles CM, Phillips TA, Metheny T, Petroff BK, et al. Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer. Cancer Prev Res (Philadelphia, Pa). 2015;8(12):1146-55.
Godinho Mota JCM, Martins KA, Mota JF, Freitas-Junior R. Excesso de peso e de gordura androide em mulheres goianas recémdiagnosticadas com câncer de mama. RBM. 2016;26(2):50-5.
Johansson H, Kanis J, Oden A, Mccloskeye, Chapurlat R, Christiansen C, et al. A meta-analysis of the association of fracture risk and body mass index in women. J Bone Mineral Res. 2014;29(1):223-33.
Jacobs ET, Kohler LN, Kunihiro AG, Jurutka PW. Vitamin D and Colorectal, Breast, and Prostate Cancers: A Review of the Epidemiological Evidence. J Cancer. 2016;7(3):232-40.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Larissa Vaz Gonçalves, Sara Socorro Faria, Jordana Carolina Marques Godinho Mota, Karine Anusca Martins, Ruffo Freitas-Junior
This work is licensed under a Creative Commons Attribution 4.0 International License.
